Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis.
cytokines
insulin resistance
metabolic syndrome
non-alcoholic fatty liver disease
tumor necrosis factor-alpha
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
22
05
2021
received:
25
03
2021
accepted:
17
07
2021
pubmed:
22
7
2021
medline:
28
1
2022
entrez:
21
7
2021
Statut:
ppublish
Résumé
To synthesize data on circulating tumor necrosis factor (TNF)-α levels between patients with histologically confirmed non-alcoholic fatty liver disease (NAFLD) (simple steatosis or non-alcoholic fatty liver [NAFL] and/or non-alcoholic steatohepatitis [NASH]) and controls. We performed a systematic search in PubMed, Scopus, and Cochrane Library. Fifty-six studies, published between 2003 and 2019, were finally included, reporting data from 5848 individuals (1634 controls and 4214 NAFLD patients). Higher circulating TNF-α levels were observed in NAFLD patients than controls (standardized mean difference [SMD] 0.84; 95% confidence interval [95% CI] 0.59-1.09), NAFL patients than controls (SMD 0.56; 95% CI 0.27-0.85), NASH patients than controls (SMD 0.93; 95% CI 0.64-1.22), and NASH than NAFL patients (SMD 0.31; 95% CI 0.16-0.46). There were only minimal changes in the comparisons between groups after excluding studies with morbidly obese populations (n = 11), or pediatric/adolescent populations (n = 6), or other than enzyme-linked immunosorbent assay method of TNF-α measurement (n = 8). There was high heterogeneity among studies in all comparisons, which was not essentially affected after sensitivity analyses. The meta-regression analysis revealed that the male ratio was positively associated with TNF-α SMD in the comparison between patients with NASH and NAFL (beta = 0.809; 95% CI 0.052-1.566) and accounted for 36% (P = 0.037) of the heterogeneity in this pair of comparison. TNF-α SMD was not associated with age, body mass index, and alanine aminotransferase in any pair of comparisons. Circulating TNF-α levels were higher in patients with NAFLD compared with controls. Higher levels of circulating TNF-α were also associated with the severity of NAFLD.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
To synthesize data on circulating tumor necrosis factor (TNF)-α levels between patients with histologically confirmed non-alcoholic fatty liver disease (NAFLD) (simple steatosis or non-alcoholic fatty liver [NAFL] and/or non-alcoholic steatohepatitis [NASH]) and controls.
METHODS
METHODS
We performed a systematic search in PubMed, Scopus, and Cochrane Library. Fifty-six studies, published between 2003 and 2019, were finally included, reporting data from 5848 individuals (1634 controls and 4214 NAFLD patients).
RESULTS
RESULTS
Higher circulating TNF-α levels were observed in NAFLD patients than controls (standardized mean difference [SMD] 0.84; 95% confidence interval [95% CI] 0.59-1.09), NAFL patients than controls (SMD 0.56; 95% CI 0.27-0.85), NASH patients than controls (SMD 0.93; 95% CI 0.64-1.22), and NASH than NAFL patients (SMD 0.31; 95% CI 0.16-0.46). There were only minimal changes in the comparisons between groups after excluding studies with morbidly obese populations (n = 11), or pediatric/adolescent populations (n = 6), or other than enzyme-linked immunosorbent assay method of TNF-α measurement (n = 8). There was high heterogeneity among studies in all comparisons, which was not essentially affected after sensitivity analyses. The meta-regression analysis revealed that the male ratio was positively associated with TNF-α SMD in the comparison between patients with NASH and NAFL (beta = 0.809; 95% CI 0.052-1.566) and accounted for 36% (P = 0.037) of the heterogeneity in this pair of comparison. TNF-α SMD was not associated with age, body mass index, and alanine aminotransferase in any pair of comparisons.
CONCLUSIONS
CONCLUSIONS
Circulating TNF-α levels were higher in patients with NAFLD compared with controls. Higher levels of circulating TNF-α were also associated with the severity of NAFLD.
Substances chimiques
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3002-3014Informations de copyright
© 2021 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Polyzos SA, Kang ES, Boutari C, Rhee EJ, Mantzoros CS. Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis. Metabolism 2020; 111S: 154203.
Polyzos SA, Mantzoros CS. Nonalcoholic fatty future disease. Metabolism 2016; 65: 1007-1016.
Polyzos SA, Kountouras J, Mantzoros CS. Adipokines in nonalcoholic fatty liver disease. Metabolism 2016; 65: 1062-1079.
Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism 2011; 60: 313-326.
Polyzos SA, Aronis KN, Kountouras J, Raptis DD, Vasiloglou MF, Mantzoros CS. Circulating leptin in non-alcoholic fatty liver disease: a systematic review and meta-analysis. Diabetologia 2015; 59: 30-43.
Polyzos SA, Kountouras J, Zavos C. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease. Hippokratia 2009; 13: 127.
Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000; 343: 1467-1476.
Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
Martin-Rodriguez JL, Gonzalez-Cantero J, Gonzalez-Cantero A et al. Insulin resistance and NAFLD: relationship with intrahepatic iron and serum TNF-α using 1H MR spectroscopy and MRI. Diabetes Metab. 2019; 45: 473-479.
Ajmal MR, Yaccha M, Malik MA et al. Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of cardiovascular diseases and its association with hs-CRP and TNF-α. Indian Heart J. 2014; 66: 574-579.
Stroup DF, Berlin JA, Morton SC et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283: 2008-2012.
Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am. J. Gastroenterol. 1999; 94: 2467-2474.
Kleiner DE, Brunt EM, Van NM et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann. Intern. Med. 2009; 151: 264-269.
Abdel-Razik A, Mousa N, Shabana W et al. A novel model using mean platelet volume and neutrophil to lymphocyte ratio as a marker of nonalcoholic steatohepatitis in NAFLD patients: multicentric study. Eur. J. Gastroenterol. Hepatol. 2016; 28: e1-e9.
Abiru S, Migita K, Maeda Y et al. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006; 26: 39-45.
Afonso MB, Rodrigues PM, Carvalho T et al. Necroptosis is a key pathogenic event in human and experimental murine models of non-alcoholic steatohepatitis. Clin. Sci. (Lond.) 2015; 129: 721-739.
Aigner E, Theurl I, Theurl M et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 2008; 87: 1374-1383.
Ajmera V, Perito ER, Bass NM et al. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017; 65: 65-77.
Alisi A, Manco M, Devito R, Piemonte F, Nobili V. Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J. Pediatr. Gastroenterol. Nutr. 2010; 50: 645-649.
Alvares-da-Silva MR, de Oliveira CP, Stefano JT et al. Pro-atherosclerotic markers and cardiovascular risk factors one year after liver transplantation. World J. Gastroenterol. 2014; 20: 8667-8673.
Baltieri L, Chaim EA, Chaim FDM, Utrini MP, Gestic MA, Cazzo E. Correlation between nonalcoholic fatty liver disease features and levels of adipokines and inflammatory cytokines among morbidly obese individuals. Arq. Gastroenterol. 2018; 55: 247-251.
Bertola A, Bonnafous S, Anty R et al. Hepatic expression patterns of inflammatory and immune response genes associated with obesity and NASH in morbidly obese patients. PLoS ONE 2010; 5: e13577.
Boga S, Koksal AR, Alkim H et al. Plasma pentraxin 3 differentiates nonalcoholic steatohepatitis (NASH) from non-NASH. Metab. Syndr. Relat. Disord. 2015; 13: 393-399.
Casoinic F, Sampelean D, Buzoianu AD, Hancu N, Baston D. Serum levels of cytokines and adipokines in patients with non-alcoholic steatohepatitis and type 2 diabetes mellitus. Hum. Veterin. Med. 2016; 8: 77-84.
Chellali S, Boudiba A, Griene L, Koceir EA. Incretins-adipocytokines interactions in type 2 diabetic subjects with or without non-alcoholic fatty liver disease: interest of GLP-1 (glucagon-like peptide-1) as a modulating biomarker. Ann. Biol. Clin. (Paris) 2019; 77: 261-271.
Coulon S, Francque S, Colle I et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012; 59: 442-449.
Das SK, Balakrishnan V. Role of cytokines in the pathogenesis of non-alcoholic fatty liver disease. Indian J. Clin. Biochem. 2011; 26: 202-209.
du Plessis J, van Pelt J, Korf H et al. Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease. Gastroenterology 2015; 149: 635-648.
Durazzo M, Niro G, Premoli A et al. Type 1 autoimmune hepatitis and adipokines: new markers for activity and disease progression? J. Gastroenterol. 2009; 44: 476-482.
Ezquerro S, Mocha F, Fruhbeck G et al. Ghrelin reduces TNF-alpha-induced human hepatocyte apoptosis, autophagy, and pyroptosis: role in obesity-associated NAFLD. J. Clin. Endocrinol. Metab. 2019; 104: 21-37.
Federico A, Dallio M, Masarone M et al. Evaluation of the effect derived from silybin with vitamin D and vitamin E administration on clinical, metabolic, endothelial dysfunction, oxidative stress parameters, and serological worsening markers in nonalcoholic fatty liver disease patients. Oxid. Med. Cell. Longev. 2019; 2019: 8742075.
Fitzpatrick E, Dew TK, Quaglia A, Sherwood RA, Mitry RR, Dhawan A. Analysis of adipokine concentrations in paediatric non-alcoholic fatty liver disease. Pediatr. Obes. 2012; 7: 471-479.
Floreani A, Variola A, Niro G et al. Plasma adiponectin levels in primary biliary cirrhosis: a novel perspective for link between hypercholesterolemia and protection against atherosclerosis. Am. J. Gastroenterol. 2008; 103: 1959-1965.
Gangarapu V, Ince AT, Baysal B et al. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur. J. Gastroenterol. Hepatol. 2015; 27: 840-845.
Gao W, Du X, Lei L et al. NEFA-induced ROS impaired insulin signalling through the JNK and p38MAPK pathways in non-alcoholic steatohepatitis. J. Cell. Mol. Med. 2018; 22: 3408-3422.
Georgoulis M, Fragopoulou E, Kontogianni MD et al. Blood redox status is associated with the likelihood of nonalcoholic fatty liver disease irrespectively of diet's total antioxidant capacity. Nutr. Res. 2015; 35: 41-48.
Haukeland JW, Damas JK, Konopski Z et al. Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J. Hepatol. 2006; 44: 1167-1174.
Heebøll S, Kreuzfeldt M, Hamilton-Dutoit S et al. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2016; 51: 456-463.
Hendrikx T, Walenbergh SMA, Jeurissen MLJ et al. Plasma IL-1 receptor antagonist levels correlate with the development of non-alcoholic steatohepatitis. Biomark. Med. 2015; 9: 1301-1309.
Jamali R, Arj A, Razavizade M, Aarabi MH. Prediction of nonalcoholic fatty liver disease via a novel panel of serum adipokines. Medicine 2016; 95: e2630.
Jarrar MH, Baranova A, Collantes R et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2008; 27: 412-421.
Kalhan SC, Edmison J, Marczewski S et al. Methionine and protein metabolism in non-alcoholic steatohepatitis: evidence for lower rate of transmethylation of methionine. Clin. Sci. (Lond.) 2011; 121: 179-189.
Kapil S, Duseja A, Sharma BK et al. Small intestinal bacterial overgrowth and toll-like receptor signaling in patients with non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 2016; 31: 213-221.
Kar S, Paglialunga S, Jaycox SH, Islam R, Paredes AH. Assay validation and clinical performance of chronic inflammatory and chemokine biomarkers of NASH fibrosis. PLoS ONE 2019; 14: e0217263.
Kashyap SR, Diab DL, Baker AR et al. Triglyceride levels and not adipokine concentrations are closely related to severity of nonalcoholic fatty liver disease in an obesity surgery cohort. Obesity (Silver Spring) 2009; 17: 1696-1701.
Kaya M, Isik D, Bestas R et al. Increased bone mineral density in patients with non-alcoholic steatohepatitis. World J. Hepatol. 2013; 5: 627-634.
Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M. Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int. 2012; 32: 279-286.
Krawczyk K, Szczesniak P, Kumor A et al. Adipohormones as prognostric markers in patients with nonalcoholic steatohepatitis (NASH). J. Physiol. Pharmacol. 2009; 60: 71-75.
Kugelmas M, Hill DB, Vivian B, Marsano L, McClain CJ. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419.
Leite NC, Salles GF, Cardoso CR, Villela-Nogueira CA. Serum biomarkers in type 2 diabetic patients with non-alcoholic steatohepatitis and advanced fibrosis. Hepatol. Res. 2013; 43: 508-515.
Lesmana CR, Lesmana LA, Akbar N et al. Clinical picture, insulin resistance, and adipocytokines profiles of nonalcoholic steatohepatitis (NASH) patients in Indonesia. Acta Med. Indones. 2009; 41: 6-10.
Loguercio C, De Simone T, D'Auria MV et al. Non-alcoholic fatty liver disease: a multicentre clinical study by the Italian Association for the Study of the Liver. Dig. Liver Dis. 2004; 36: 398-405.
Mager DR, Yap J, Rodriguez-Dimitrescu C, Mazurak V, Ball G, Gilmour S. Anthropometric measures of visceral and subcutaneous fat are important in the determination of metabolic dysregulation in boys and girls at risk for nonalcoholic fatty liver disease. Nutr. Clin. Pract. 2013; 28: 101-111.
Manco M, Marcellini M, Giannone G, Nobili V. Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease. Am. J. Clin. Pathol. 2007; 127: 954-960.
Musso G, Gambino R, Durazzo M et al. Adipokines in NASH: postprandial lipid metabolism as a link between adiponectin and liver disease. Hepatology 2005; 42: 1175-1183.
Nobili V, Alisi A, Cutrera R et al. Altered gut-liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax 2015; 70: 769-781.
Perez-Carreras M, Del Hoyo P, Martin MA et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003; 38: 999-1007.
Polyzos SA, Kountouras J, Papatheodorou A et al. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index. Ann. Hepatol. 2013; 12: 749-757.
Poniachik J, Csendes A, Diaz JC et al. Increased production of IL-1alpha and TNF-alpha in lipopolysaccharide-stimulated blood from obese patients with non-alcoholic fatty liver disease. Cytokine 2006; 33: 252-257.
Purnomo HD, Kasno SE et al. The roles of metabolic syndrome and several biomarkers in incidence and severity of non-alcoholic fatty liver disease. Hiroshima J. Med. Sci. 2018; 67: 138-146.
Rabelo F, Oliveira CP, Faintuch J et al. Pro- and anti-inflammatory cytokines in steatosis and steatohepatitis. Obes. Surg. 2010; 20: 906-912.
Ruiz AG, Casafont F, Crespo J et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes. Surg. 2007; 17: 1374-1380.
Shanab AA, Scully P, Crosbie O et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011; 56: 1524-1534.
Shimamura T, Fujisawa T, Husain SR, Kioi M, Nakajima A, Puri RK. Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model. J. Immunol. 2008; 181: 4656-4665.
Vonghia L, Magrone T, Verrijken A et al. Peripheral and hepatic vein cytokine levels in correlation with non-alcoholic fatty liver disease (NAFLD)-related metabolic, histological, and haemodynamic features. PLoS ONE 2015; 10: e0143380.
Wong VW, Hui AY, Tsang SW et al. Metabolic and adipokine profile of Chinese patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 2006; 4: 1154-1161.
Yalniz M, Bahcecioglu IH, Ataseven H et al. Serum adipokine and ghrelin levels in nonalcoholic steatohepatitis. Mediators Inflamm. 2006; 2006: 34295.
Yang HR, Ko JS, Seo JK. Role of tumor necrosis factor-α promoter polymorphism and insulin resistance in the development of non-alcoholic fatty liver disease in obese children. Pediatr. Gastroenterol. Hepatol. Nutr. 2012; 15: 44-51.
Younossi ZM, Jarrar M, Nugent C et al. A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes. Surg. 2008; 18: 1430-1437.
Moher D, Pham B, Jones A et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-613.
Balakrishnan M, Patel P, Dunn-Valadez S et al. Women have a lower risk of nonalcoholic fatty liver disease but a higher risk of progression vs men: a systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2021; 19: 61-71.e15.
Lonardo A, Suzuki A. Sexual dimorphism of NAFLD in adults. Focus on clinical aspects and implications for practice and translational research. J. Clin. Med. 2020: 9.
Ballestri S, Nascimbeni F, Baldelli E, Marrazzo A, Romagnoli D, Lonardo A. NAFLD as a sexual dimorphic disease: role of gender and reproductive status in the development and progression of nonalcoholic fatty liver disease and inherent cardiovascular risk. Adv. Ther. 2017; 34: 1291-1326.
Lonardo A, Nascimbeni F, Ballestri S et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identification of research gaps. Hepatology 2019; 70: 1457-1469.
Marucci A, Mangiacotti D, di Mauro L, Antonacci M, Trischitta V, Di Paola R. Sex-specific effect of BMI on insulin sensitivity and TNF-α expression. Acta Diabetol. 2015; 52: 413-416.
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
Wandrer F, Liebig S, Marhenke S et al. TNF-receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis. 2020; 11: 212.
Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J. Biol. Chem. 2012; 287: 40161-40172.
Aparicio-Vergara M, Hommelberg PP, Schreurs M et al. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology 2013; 57: 566-576.
D'Haens GR, van Deventer S. 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 2021; 70: 1396-1405.
Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J. Hepatol. 2020; 73: 202-209.
Polyzos SA, Kang ES, Tsochatzis EA et al. Commentary: nonalcoholic or metabolic dysfunction-associated fatty liver disease? The epidemic of the 21st century in search of the most appropriate name. Metabolism 2020; 113: 154413.